Rest Haven-york | |
1050 South George Street, York, Pennsylvania 17403 | |
(717) 843-9866 | |
Name | Rest Haven-york |
---|---|
Location | 1050 South George Street, York, Pennsylvania |
Certified By | Medicare and Medicaid |
No. of Certified Beds | 159 |
Occupancy Rate | 60.25% |
Medicare ID (CCN) | 395058 |
Legal Business Name | Hes Inc |
Ownership Type | For Profit - Corporation |
NPI Number | 1346238672 |
Organization Name | HES INC |
Doing Business As | REST HAVEN - YORK |
Address | 1050 S George St, York, PA 17403 |
Phone Number | 717-843-9866 |
News Archive
bioTheranostics, a bioMerieux company that discovers, develops and commercializes innovative molecular diagnostic tests in oncology, announces the launch of an expanded tumor-type database for its flagship product, CancerTYPE ID®, and the launch of KRAS mutational testing.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a recent "refuse to file" (RTF) letter issued by the Food and Drug Administration (FDA) regarding Merck Serono's oral cladribine has heightened the competition between oral cladribine and its primary competitor, Novartis/Mitsubishi Tanabe's FTY-720 (fingolimod), to be the first oral disease-modifying multiple sclerosis therapy to reach the market in the United States.
The newly developed STED-RICS microscopy method records rapid movements of molecules in live samples. By combining raster image correlation spectroscopy (RICS) with STED fluorescence microscopy, researchers of Karlsruhe Institute of Technology (KIT) opened up new applications in medical research, e.g. analyzing the dynamics of cell membranes at high protein concentrations.
The U.S. Food and Drug Administration today approved a new indication for Tasigna (nilotinib) for the treatment of a rare blood cancer when it is first diagnosed. The cancer, called Philadelphia chromosome positive chronic phase chronic myeloid leukemia (Ph+ CP-CML), is a slowly progressing blood and bone marrow disease linked to a genetic abnormality.
› Verified 4 days ago
Ratings from Surveys (Inspections): | |
Ratings from Quality Measures: | |
Ratings from Staffing Data: | |
Overall Rating: |
---|
News Archive
bioTheranostics, a bioMerieux company that discovers, develops and commercializes innovative molecular diagnostic tests in oncology, announces the launch of an expanded tumor-type database for its flagship product, CancerTYPE ID®, and the launch of KRAS mutational testing.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a recent "refuse to file" (RTF) letter issued by the Food and Drug Administration (FDA) regarding Merck Serono's oral cladribine has heightened the competition between oral cladribine and its primary competitor, Novartis/Mitsubishi Tanabe's FTY-720 (fingolimod), to be the first oral disease-modifying multiple sclerosis therapy to reach the market in the United States.
The newly developed STED-RICS microscopy method records rapid movements of molecules in live samples. By combining raster image correlation spectroscopy (RICS) with STED fluorescence microscopy, researchers of Karlsruhe Institute of Technology (KIT) opened up new applications in medical research, e.g. analyzing the dynamics of cell membranes at high protein concentrations.
The U.S. Food and Drug Administration today approved a new indication for Tasigna (nilotinib) for the treatment of a rare blood cancer when it is first diagnosed. The cancer, called Philadelphia chromosome positive chronic phase chronic myeloid leukemia (Ph+ CP-CML), is a slowly progressing blood and bone marrow disease linked to a genetic abnormality.
› Verified 4 days ago
Number of Facility Reported Incidents | 0 |
Number of Substantiated Complaints | 0 |
Number of Fines | 0 |
Total Amount of Fines in Dollars | $0 |
Number of Payment Denials | 0 |
Total Number of Penalties | 0 |
Experience Measure | Provider | National Avg. |
---|---|---|
Percentage of long-stay residents whose need for help with daily activities has increased | 7.37 | 14.46 |
Percentage of long-stay residents who lose too much weight | 9.19 | 5.51 |
Percentage of low risk long-stay residents who lose control of their bowels or bladder | 69.05 | 48.41 |
Percentage of long-stay residents with a catheter inserted and left in their bladder | 1.34 | 1.79 |
Percentage of long-stay residents with a urinary tract infection | 1.28 | 2.65 |
Percentage of long-stay residents who have depressive symptoms | 8.62 | 5.05 |
Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
Percentage of long-stay residents experiencing one or more falls with major injury | 1.77 | 3.36 |
Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 96.97 | 93.87 |
Percentage of long-stay residents who received an antipsychotic medication | 14.75 | 14.2 |
Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 76.24 | 83.88 |
Percentage of short-stay residents who newly received an antipsychotic medication | 1.04 | 1.79 |
Percentage of long-stay residents whose ability to move independently worsened | 29.74 | 17.09 |
Percentage of long-stay residents who received an antianxiety or hypnotic medication | 16.27 | 19.7 |
Percentage of high risk long-stay residents with pressure ulcers | 6.59 | 7.32 |
Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 98.21 | 95.98 |
Percentage of short-stay residents who made improvements in function | 63.84 | 67.99 |
Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 82.43 | 82.93 |
News Archive
bioTheranostics, a bioMerieux company that discovers, develops and commercializes innovative molecular diagnostic tests in oncology, announces the launch of an expanded tumor-type database for its flagship product, CancerTYPE ID®, and the launch of KRAS mutational testing.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a recent "refuse to file" (RTF) letter issued by the Food and Drug Administration (FDA) regarding Merck Serono's oral cladribine has heightened the competition between oral cladribine and its primary competitor, Novartis/Mitsubishi Tanabe's FTY-720 (fingolimod), to be the first oral disease-modifying multiple sclerosis therapy to reach the market in the United States.
The newly developed STED-RICS microscopy method records rapid movements of molecules in live samples. By combining raster image correlation spectroscopy (RICS) with STED fluorescence microscopy, researchers of Karlsruhe Institute of Technology (KIT) opened up new applications in medical research, e.g. analyzing the dynamics of cell membranes at high protein concentrations.
The U.S. Food and Drug Administration today approved a new indication for Tasigna (nilotinib) for the treatment of a rare blood cancer when it is first diagnosed. The cancer, called Philadelphia chromosome positive chronic phase chronic myeloid leukemia (Ph+ CP-CML), is a slowly progressing blood and bone marrow disease linked to a genetic abnormality.
› Verified 4 days ago
Promedica Skilled Nrsg And Rehab (kingston Court) Location: 2400 Kingston Court, York, Pennsylvania 17402 Phone: (717) 755-8811 | |
Colonial Manor Nursing Home Location: 970 Colonial Avenue, York, Pennsylvania 17403 Phone: (717) 845-2661 | |
Pleasant Acres Rehabilitation And Nursing Center Location: 118 Pleasant Acres Rd,rd7, York, Pennsylvania 17402 Phone: (717) 840-7100 | |
Promedica Skilled Nrsg And Rehab (york South) Location: 200 Pauline Drive, York, Pennsylvania 17402 Phone: (717) 741-0824 | |
Promedica Skilled Nrsg And Rehab (york North) Location: 1770 Barley Road, York, Pennsylvania 17408 Phone: (717) 767-6530 |